文献速递核素与放射性配体治疗骨显像与常规 SPECT

[177Lu]镥-羟基磷灰石放射性滑膜切除术治疗难治性慢性炎性膝关节炎

[177Lu]Lutetium-hydroxyapatite radiosynovectomy in refractory chronic inflammatory arthritis of the knee joint.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-12

前瞻性研究纳入22例患者共24个难治性慢性炎性膝关节炎膝关节,行关节腔内注射[177Lu]Lu-羟基磷灰石放射性滑膜切除术。3个月时18个膝关节为应答者、6个为非应答者,临床评分在1个月时显著改善并持续至3个月(p < 0.05),三相骨扫描血池活性变化不显著,不良反应轻微且不显著。

要点

  • 22例患者24个难治性慢性炎性膝关节炎膝关节接受[177Lu]Lu-羟基磷灰石放射性滑膜切除术。
  • 3个月时18个膝关节为应答者,6个为非应答者。
  • 临床评分1个月显著改善并持续至3个月(p < 0.05),血池活性变化不显著。

核心结论

  • 本研究证实[177Lu]Lu-羟基磷灰石放射性滑膜切除术对常规药物治疗难治的慢性炎性膝关节炎患者安全有效。

研究设计与样本

  • 前瞻性研究,纳入22例难治性慢性炎性关节炎患者的24个膝关节。
  • 所有患者临床评估疼痛、压痛、活动度、镇痛药用量和牛津膝关节评分,并基于三相骨扫描血池活性进行闪烁显像评估。
  • 膝关节放射性滑膜切除术采用关节腔内注射[177Lu]Lu-羟基磷灰石,临床评估在1个月和3个月进行,闪烁显像评估在3个月进行。

主要发现

  • 24个膝关节中,3个月时18个为应答者,6个为非应答者。
  • 放射性滑膜切除术后1个月临床评分显著改善,并持续至术后3个月(p < 0.05)。
  • 三相骨扫描血池活性变化不显著。
  • 报告的不良反应轻微且不显著。

关键数值与推荐

  • 根据累积评分百分比变化将患者分为应答者和非应答者。
  • 临床评分改善在1个月和3个月均达统计学显著(p < 0.05)。

临床怎么用

  • 原文结论认为[177Lu]Lu-羟基磷灰石放射性滑膜切除术对常规药物治疗难治的慢性炎性膝关节炎患者安全有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the efficacy of [177Lu]Lu-Hydroxyapatite radiosynovectomy (RSV) in patients with refractory chronic inflammatory arthritis of the knee joint. MATERIALS AND METHODS: Overall, 24 knees in 22 patients with refractory chronic inflammatory arthritis were enrolled in this prospective study. All patients were assessed clinically for pain, tenderness, range of motion, analgesic intake, Oxford Knee Score, and scintigraphically based on blood pool activity on three-phase bone scan. Various scores were assigned to clinical these parameters. RSV of the knee joint was done using intra-articular injection of [177Lu]Lu-Hydroxyapatite. Patients were assessed clinically at 1 and 3 months, and scintigraphically at 3 months using blood pool index on three-phase bone scan. Patients were categorised as responders and non-responders on the basis of change in percentage of cumulative scores. RESULTS: Out of 24 knees, 18 knees were responders and 6 knees were non-responders at 3 months. There was a significant improvement in clinical scores at 1 month post-RSV, which persisted at 3 months post-RSV (p < 0.05). However, the change in blood pool activity on three-phase bone scan was not significant. Reported adverse effects were mild and not significant. CONCLUSION: This study confirmed the safety and efficacy of [177Lu]Lu-Hydroxyapatite radiosynovectomy for patients with chronic inflammatory knee joint arthritis refractory to conventional medical treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sarwal T, Kumar R, Taywade S, et al. [177Lu]Lutetium-hydroxyapatite radiosynovectomy in refractory chronic inflammatory arthritis of the knee joint. Eur J Nucl Med Mol Imaging. 2025. PMID: 40794282. doi:10.1007/s00259-025-07496-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。